These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17503971)

  • 1. Evidence of switching antipsychotic therapy to improve metabolic disturbances.
    Wieden PJ; Newcomer JW
    J Clin Psychiatry; 2007 May; 68(5):e13. PubMed ID: 17503971
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone-associated increase in triglyceride levels.
    Weinbrenner A; Peus V; Inta D; Englisch S; Zink M
    Am J Psychiatry; 2009 Jan; 166(1):113-4. PubMed ID: 19122019
    [No Abstract]   [Full Text] [Related]  

  • 3. The risks and benefits of switching antipsychotics: a case study approach.
    Weber M; Gutierrez AM; Mohammadi M
    Perspect Psychiatr Care; 2009 Jan; 45(1):54-61. PubMed ID: 19154240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyslipidemia and schizophrenia].
    Wetterling T; Schneider B; Weber B
    Psychiatr Prax; 2007 Jul; 34(5):223-9. PubMed ID: 17160750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations].
    Martínez Romero G; Peris Martí JF; Gomar Fayos J; Navarro Gosalbez M; Quintana Vargas I; Muelas Tirado J
    Farm Hosp; 2010; 34(3):139-47. PubMed ID: 20434929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
    J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
    Meltzer HY
    J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an anti-fat bias among schizophrenia patients?
    Pierson KE
    Obesity (Silver Spring); 2006 Dec; 14(12):2305. PubMed ID: 17189559
    [No Abstract]   [Full Text] [Related]  

  • 12. Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.
    Yan H; Chen JD; Zheng XY
    Psychopharmacology (Berl); 2013 Sep; 229(1):1-7. PubMed ID: 23832387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of schizophrenia: what experts are recommending.
    Harv Ment Health Lett; 2004 Oct; 21(4):4-7. PubMed ID: 15496354
    [No Abstract]   [Full Text] [Related]  

  • 14. Interventions to reduce weight gain in schizophrenia.
    Faulkner G; Cohn T; Remington G
    Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900
    [No Abstract]   [Full Text] [Related]  

  • 15. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.
    Henderson DC; Cagliero E; Gray C; Nasrallah RA; Hayden DL; Schoenfeld DA; Goff DC
    Am J Psychiatry; 2000 Jun; 157(6):975-81. PubMed ID: 10831479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assessment and management of antipsychotic-associated metabolic disturbances from a psychiatric perspective.
    Chue P
    Can J Psychiatry; 2004 Mar; 49(3):200-7. PubMed ID: 15101503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.
    Yamamoto K; Fukuda M; Nogawa A; Takahashi E; Miyaoka H
    J Clin Psychiatry; 2007 May; 68(5):802. PubMed ID: 17503998
    [No Abstract]   [Full Text] [Related]  

  • 19. Follow-up interventions in persons with schizophrenia and metabolic syndrome.
    Kølbæk P; Schiöth E; Aagaard J; Munk-Jørgensen P
    Aust N Z J Psychiatry; 2014 Nov; 48(11):1059-60. PubMed ID: 25277542
    [No Abstract]   [Full Text] [Related]  

  • 20. Consensus development conference on antipsychotic drugs and obesity and diabetes.
    ; ; ;
    J Clin Psychiatry; 2004 Feb; 65(2):267-72. PubMed ID: 15003083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.